Alkermes plc. Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Gain
Alkermes plc. (ALKS) had Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Gain of $88.00 thousand as of 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale and Held-to-Maturity, Fair Value to Amortized Cost, after Allowance for Credit Loss
us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedGain · last filed 2026-07-28
- 2026-06-30: Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Gain $88.00K.
- 2026-03-31: Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Gain $303.00K.
- 2025-12-31: Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Gain $872.00K.
- 2025-09-30: Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Gain $2.30M.
| Period end | Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Gain |
|---|---|
| 2026-06-30 | $88.00K 10-Q · filed 2026-07-28 |
| 2026-03-31 | $303.00K 10-Q · filed 2026-05-05 |
| 2025-12-31 | $872.00K 10-Q · filed 2026-07-28 |
| 2025-09-30 | $2.30M 10-Q · filed 2025-10-28 |
| 2025-06-30 | $1.92M 10-Q · filed 2025-07-29 |
| 2025-03-31 | $1.90M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $1.52M 10-K · filed 2026-02-25 |
| 2024-09-30 | $3.71M 10-Q · filed 2024-10-24 |
| 2024-06-30 | $229.00K 10-Q · filed 2024-07-24 |
| 2023-12-31 | $1.46M 10-K · filed 2025-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |